Overview

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Status:
Active, not recruiting

Trial end date:
2021-12-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Phase:

Phase 3

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company

Treatments:

Bumetanide
Pharmaceutical Solutions